Brca1-Associated Breast Cancer Model

Conditional Knockout

Brca1 Associated Breast Cancer Conditional Knockout Mouse Model
EZcohort® Models
The easiest way to acquire and breed cryopreserved GEMs
This model is available for immediate cryorecovery.

Mixed Background

  • Model #
  • Genotype
  • Nomenclature
  • 11510
    STOCK Trp53tm1Brn Brca1tm1Brn Tg(KRT14-cre)8Brn
  • Breast cancer model driven by tissue specific deletion of Brca1 and p53 in epithelial cells.
  • Conditional mouse mutant with somatic deletion of Brca1 and Trp53 in several epithelial tissues including mammary epithelium and skin. Female mice of this strain show a high incidence of mammary tumors that mimic many aspects of human BRCA1-mutated basal-like breast cancer.
  • Contains conditional disruptions of the Brca1 gene, germline mutations of which are responsible for 40% to 50% of hereditary breast cancers, and the Trp53 tumor suppressor gene, the most commonly mutated gene in human cancers.
  • Literature references report that 80% of females develop mammary tumors with a tumor onset between 140 and 280 days.
  • This model may be helpful in predicting responses of human BRCA1-deficient tumors to therapies.
  • Can be used to supply tumor tissues for allografts.
  • Non mammary epithelial skin tumors are reported to develop in 20-30% of mice.


This mouse line was developed in the laboratory of Jos Jonkers of the Netherlands Cancer Institute (NKI). The model was developed by mating conditional Trp53 mice with K14Cre transgenic mice, and the resultant offspring were crossed with conditional Brca1 mice. The conditional Brca1 mouse was generated by injection of ES cells containing a Brca1 allele with floxed exons 5-13 into C57BL/6 blastocysts. Resultant chimeras were crossed with FVB/N mice to produce outbred heterozygous offspring (Liu 2007). The conditional Trp53 mouse was generated by targeting a 13.5 kb genomic clone encompassing Trp53 exons 1-11 in 129P2-derived ES cells of the E14 sub-clone IB10. Targeted ES cells were injected into C57BL/6 blastocysts and resulting chimeras were crossed with FVB/N mice to produce outbred heterozygous offspring (Jonkers 2001). The K14cre transgenic mice were derived by pronuclear injection of the transgene into FVB/N one-cell stage embryos according to standard procedures. The K14cre transgene includes a 2.1 kb human K14 gene promoter fragment followed by a 0.65 kb rabbit β-globin intron, the Cre coding sequences and a 0.63 kb transcription termination/polyadenylation fragment of the human growth hormone gene (Jonkers 2001). Taconic received stock in 2011, and the line was derived by embryo transfer. The colony was maintained by mating females which are homozygous for both of the floxed genes and wild type for the Cre with males which are homozygous for both of the floxed genes and carriers for the Cre.





Initial Publication:

Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M and Berns A. (2001). Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 29, 418-425.

Liu X, Holstege H, van der Gulden H, Treur-Mulder M, Zevenhoven J, Velds A, Kerkhoven RM, van Vliet MH, Wessels LF, Peterse JL, Berns A, Jonkers J. (2007) Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A. 2007 104(29):12111-6.
Additional Publications:

Rottenberg S, Nygren AO, Pajic M, van Leeuwen FW, van der Heijden I, van de Wetering K, Liu X, de Visser KE, Gilhuijs KG, van Tellingen O, Schouten JP, Jonkers J, Borst P. (2007) Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci U S A. 104(29):12117-22.

Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, Boulter R, Cranston A, O'Connor MJ, Martin NM, Borst P, Jonkers J. (2008) High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 105(44):17079-84.

Pajic M, Iyer JK, Kersbergen A, van der Burg E, Nygren AO, Jonkers J, Borst P, Rottenberg S. (2009) Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer. Cancer Res. 69(16):6396-404.

van Leeuwen FW, Buckle T, Kersbergen A, Rottenberg S, Gilhuijs KG. (2009) Noninvasive functional imaging of P-glycoprotein-mediated doxorubicin resistance in a mouse model of hereditary breast cancer to predict response, and assign P-gp inhibitor sensitivity. Eur J Nucl Med Mol Imaging. 36(3):406-12.

Issaeva N, Thomas HD, Djureinovic T, Jaspers JE, Stoimenov I, Kyle S, Pedley N, Gottipati P, Zur R, Sleeth K, Chatzakos V, Mulligan EA, Lundin C, Gubanova E, Kersbergen A, Harris AL, Sharma RA, Rottenberg S, Curtin NJ, Helleday T. (2010) 6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. Cancer Res. 70(15):6268-76.

Pajic M, Kersbergen A, van Diepen F, Pfauth A, Jonkers J, Borst P, Rottenberg S. (2010) Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo. Cell Cycle. 9(18):3780-91.

Zander SA, Kersbergen A, van der Burg E, de Water N, van Tellingen O, Gunnarsdottir S, Jaspers JE, Pajic M, Nygren AO, Jonkers J, Borst P, Rottenberg S. (2010) Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. Cancer Res. 70(4):1700-10.

Rottenberg S, Vollebergh MA, de Hoon B, de Ronde J, Schouten PC, Kersbergen A, Zander SA, Pajic M, Jaspers JE, Jonkers M, Lodén M, Sol W, van der Burg E, Wesseling J, Gillet JP, Gottesman MM, Gribnau J, Wessels L, Linn SC, Jonkers J, Borst P. (2012) Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors. Cancer Res. 72(9):2350-61.

Zander SA, Kersbergen A, Sol W, Gonggrijp M, van de Wetering K, Jonkers J, Borst P, Rottenberg S. (2012) Lack of ABCG2 shortens latency of BRCA1-deficient mammary tumors and this is not affected by genistein or resveratrol. Cancer Prev Res (Phila). 5(8):1053-60.

Zander SA, Sol W, Greenberger L, Zhang Y, van Tellingen O, Jonkers J, Borst P, Rottenberg S. (2012) EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors. PLoS One. 7(9):e45248.

Warmoes M, Jaspers JE, Xu G, Sampadi BK, Pham TV, Knol JC, Piersma SR, Boven E, Jonkers J, Rottenberg S, Jimenez CR. (2013) Proteomics of genetically engineered mouse mammary tumors identifies fatty acid metabolism members as predictive markers for cisplatin resistance. Mol Cell Proteomics. Feb 8.

To purchase this EZcohort model, sign the Terms of Sale (choose from the list below) and email it directly to

This model is sold under terms which grant perpetual use rights.

Welcome! Tell us a little about yourself